2.1050
-0.0250
(-1.17%)
At close: January 30 at 6:29:37 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
28,567.0000
28,567.0000
27,426.0000
21,109.0000
16,654.0000
Operating Income
-28,567.0000
-28,567.0000
-27,426.0000
-21,109.0000
-16,654.0000
Net Non Operating Interest Income Expense
-2,383.0000
-2,383.0000
-1,349.0000
-230.0000
-53.0000
Pretax Income
-30,944.0000
-30,944.0000
-28,730.0000
-21,178.0000
-16,934.0000
Tax Provision
--
--
--
16.0000
10.0000
Net Income Common Stockholders
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Diluted NI Available to Com Stockholders
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Basic EPS
-0.48
-0.48
-0.52
-0.42
-0.37
Diluted EPS
-0.48
-0.48
-0.52
-0.42
-0.37
Basic Average Shares
65,055.0360
65,055.0360
55,229.8350
50,723.9640
45,712.1110
Diluted Average Shares
65,055.0360
65,055.0360
55,229.8350
50,723.9640
45,712.1110
Total Operating Income as Reported
-28,568.0000
-28,568.0000
-27,426.0000
-21,108.0000
-16,654.0000
Rent Expense Supplemental
320.0000
320.0000
114.0000
7.0000
--
Total Expenses
28,567.0000
28,567.0000
27,426.0000
21,109.0000
16,654.0000
Net Income from Continuing & Discontinued Operation
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Normalized Income
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Interest Income
230.0000
230.0000
11.0000
2.0000
109.0000
Interest Expense
2,167.0000
2,167.0000
1,373.0000
215.0000
149.0000
Net Interest Income
-2,383.0000
-2,383.0000
-1,349.0000
-230.0000
-53.0000
EBIT
-28,777.0000
-28,777.0000
-27,357.0000
-20,963.0000
-16,785.0000
EBITDA
-28,431.0000
-28,431.0000
-27,057.0000
-20,657.0000
-16,502.0000
Reconciled Depreciation
346.0000
346.0000
300.0000
306.0000
283.0000
Net Income from Continuing Operation Net Minority Interest
-30,944.0000
-30,944.0000
-28,730.0000
-21,194.0000
-16,944.0000
Normalized EBITDA
-28,431.0000
-28,431.0000
-27,057.0000
-20,657.0000
-16,502.0000
Tax Rate for Calcs
--
--
--
0.0002
0.0002
12/31/2020 - 12/3/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HRTIS.HE Herantis Pharma Oyj
1.5800
-1.86%
NANOFH.HE Nanoform Finland Oyj
1.2280
-0.16%
BIOBV.HE Biohit Oyj
2.9900
+2.75%
AELIS.PA Aelis Farma SA
3.7600
-21.67%
ISOFOL.ST Isofol Medical AB (publ)
2.1150
-2.76%
ACE.ST Ascelia Pharma AB (publ)
2.8600
+2.88%
NWRN.SW Newron Pharmaceuticals S.p.A.
9.42
-0.84%
VLA.PA Valneva SE
2.4600
+4.15%
F6T.MU Fate Therapeutics Inc
1.2810
0.00%
ATORX.ST Alligator Bioscience AB (publ)
0.0325
-12.16%